Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III

In this webinar, a detailed discussion is done on the understanding of the molecular differences between EGFR AXON 19 Deletion & EXON 21 L858R Mutatio

Speakers : Dr Pushpak Chirmade ,Dr Shailesh Bondarde ,Dr Kaushal Patel ,Dr Suhas Aagre ,Dr Sandip Ganguly

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II

In this webinar, a detailed discussion is done on the understanding of the molecular differences between EGFR AXON 19 Deletion & EXON 21 L858R Mutatio

Speakers : Dr Pushpak Chirmade ,Dr Shailesh Bondarde ,Dr Kaushal Patel ,Dr Suhas Aagre ,Dr Sandip Ganguly

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I

In this webinar, a detailed discussion is done on the understanding of the molecular differences between EGFR AXON 19 Deletion & EXON 21 L858R Mutatio

Speakers : Dr Sandip Ganguly ,Dr Suhas Aagre ,Dr Kaushal Patel ,Dr Shailesh Bondarde ,Dr Pushpak Chirmade

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Harish P ,Dr. Sai Vivek ,Dr. Ananth Pai ,Dr Vijay Agarwal

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Harish P ,Dr. Sai Vivek ,Dr. Ananth Pai ,Dr Vijay Agarwal

Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2

Explore the impact of CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, drawing insights from the pivotal PALOMA-2 study presented by Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.

Explore the multifaceted advantages of CDK4/6 inhibitors in HR+/HER2- breast cancer, based on the PALOMA-2 study, in this insightful session with Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh


Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Dual Checkpoint Blockade Boosts Breast Cancer pCR

2.

These Medical Doctors Are Real Comedians: Should Doctors Be Funnier?

3.

Chris Hoy reveals that he has terminal cancer?here's how to spot early signs of prostate cancer

4.

Saturated Fat Tied to Worse Survival After Prostate Cancer

5.

New Standard for Newly Diagnosed Pediatric B-Cell Acute Lymphoblastic Leukemia


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot